###begin article-title 0
RAS gene polymorphisms, classical risk factors and the advent of coronary artery disease in the Portuguese population
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Several polymorphisms within the renin-angiotensin system cluster of genes have been associated with the advent of coronary artery disease (CAD) or related pathologies. We investigated the distribution of 5 of these polymorphisms in order to find any association with CAD development and distinguish if any of the biochemical and behavioural factors interact with genetic polymorphisms in the advent of the disease.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT </italic>
###xml 85 89 85 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT </italic>
###xml 156 164 <span type="species:ncbi:9606">patients</span>
ACE I/D (rs4340), ACE A11860G (rs4343), AT1R A1166C (rs5186), AGT T174M (rs4762) and AGT M235T (rs699) gene polymorphisms were PCR-RFLP analysed in 298 CAD patients and 510 controls from Portugal. Several biochemical and behavioural markers were obtained.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 15 18 15 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 111 115 111 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 125 128 125 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 408 412 408 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 426 429 426 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 615 618 615 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 708 712 708 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R</italic>
ACE I/D DD and ACE11860 GG genotypes are risk factors for CAD in this population. The simultaneous presence of ACE I/D I and ACE11860 A alleles corresponds to a significant trend towards a decrease in CAD incidence. We found several synergistic effects between the studied polymorphisms and classical risk factors such as hypertension, obesity, diabetes and dyslipidaemia: the presence of the DD genotype of ACE I/D (and also ACE11860 GG) increases the odds of developing CAD when associated to each one of these classical risk factors, particularly when considering the male and early onset CAD subgroup analysis; AGT235 TT also increases the CAD risk in the presence of hypertension and dyslipidaemia, and AT1R1166 interacts positively with hypertension, smoking and obesity.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 311 314 311 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
ACE polymorphisms were shown to play a major role in individual susceptibility to develop CAD. There is also a clear interaction between RAS predisposing genes and some biochemical/environmental risk factors in CAD onset, demonstrating a significant enhancement of classical markers particularly by ACE I/D and ACE11860.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 711 714 711 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 813 816 813 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 887 888 887 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 889 890 889 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 923 924 923 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
Cardiovascular diseases represent today the main cause of death in human adults in western populations. A reasonable number of studies have focused in testing specific genetic markers among groups of ischemic coronary artery disease (CAD) patients and control groups, aiming to find a correlation between these gene polymorphisms and disease. The renin-angiotensin system (RAS) has been shown to play a key role in the regulation of blood pressure and influence the cardiovascular system [1], and several genes belonging to this system have been associated with CAD. Two of the most intensively investigated genetic polymorphisms are the insertion/deletion (I/D) alleles of the angiotensin I-converting enzyme (ACE) gene and mutations at the angiotensin II AT1 receptor. Several mutations at the angiotensinogen (AGT) gene have also been studied as candidates in essential hypertension [2,3] or myocardial infarction (MI) [4].
###end p 11
###begin p 12
###xml 218 222 218 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 422 423 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 424 425 424 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 432 437 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 660 661 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 694 698 694 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT </italic>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 796 797 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 874 876 874 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 877 879 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 969 971 969 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 563 570 <span type="species:ncbi:9606">patient</span>
Albeit all these and other markers that have been identified in latter years as possible risk factors for several pathologies associated to CAD, a considerable number of opposing results also exist. The DD genotype of ACE for instance has been found to be linked to MI [5,6] but contrary reports also exist [7,8]. There are even conflicting reports on the assessment of risk profiles depending on the populations studied [6,9]. The AT1R A1166C polymorphism has also been subjected to opposite reports as to its role in CAD, particularly when it is related to the patient's geographic origin: it was found to be significantly associated with CAD in Caucasians [9,10] but not in Asians [11]. The AGT M235T polymorphism has been shown to be positively related to essential hypertension [12] and MI [9] but other studies found no relation at all between the marker and disease [13,14] and few reports exist to confirm an association with plasmatic AGT concentration level [14].
###end p 12
###begin p 13
###xml 212 220 <span type="species:ncbi:9606">patients</span>
In this report we have studied the distribution of genotypic and allelic frequencies at 5 loci, in two groups of individuals from Madeira Island (Portugal), an island settled mainly by the Portuguese. A group of patients with a known CAD history and a control group with no CAD related pathologies were selected. The main focus was to analyse these genetic polymorphisms, alone or combined in haplotypes, and clarify their potential association with CAD related conditions. Knowing that in most cases CAD has a multifactorial basis, involving a number of genes and environmental factors interacting to determine whether or not the disease will develop, we also tried to determine a possible interaction between the five gene polymorphisms and several well known CAD linked factors.
###end p 13
###begin title 14
Methods
###end title 14
###begin p 15
###xml 1898 1899 1890 1891 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2062 2063 2046 2047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 484 492 <span type="species:ncbi:9606">Patients</span>
The total population of this study consisted of 808 Caucasian individuals (aged between 18 and 70 years old) divided in two groups: 510 subjects without a history of CAD, MI, or stroke - excluded after a medical examination and interview - randomly selected from the electoral rows, who participated as controls, plus 298 individuals recruited from patients admitted to the Cardiology Care Unit of the Main Hospital of Funchal (Hospital Central do Funchal, Madeira Island, Portugal). Patients' recruitment satisfied the following criteria: stable coronary disease suggested by clinical analysis and proved by angiographic exam (a significant lesion was considered when >/= 75% of luminal narrowing was observed in at least one of the major arteries) or occurrence of MI as defined by the WHO criteria. This investigation is in conformity with the principles outlined in the Declaration of Helsinki and was approved by the Hospital's Ethics Committee; all subjects gave their informed consent. Cases and controls filled in a questionnaire about their personal histories - age, sex, essential hypertension, diabetes mellitus, smoking habits, overweight, sedentary habits, alcohol ingestion and family medical history - and provided blood samples for genotype analysis and biochemical measurements. The presence of traditional risk factors in both groups was determined using the criteria standardized by the European Society of Cardiology: an hypertensive condition was attributed when systolic blood pressure values were >/= 139 mm Hg and/or diastolic blood pressure values >/= 89 mm Hg in at least two separate measurements or when being medicated against hypertension; subjects were considered smokers when consuming more than five cigarettes per day or non-smokers when never smoked or had stopped smoking at least one year before sample collection; obesity was defined for BMI values >/= 30 kg/m2; dyslipidaemia was considered for plasmatic values of total cholesterol >/= 200 mg/dl, triglycerides >/= 150 mg/dl, LDL >/= 130 mg/dl and HDL </= 40 mg/dl. Table 1 gives the basic characteristics of the studied population.
###end p 15
###begin p 16
Baseline characteristics and clinical data for conventional risk factors
###end p 16
###begin p 17
Values presentation: mean +/- SD; *P < 0.05, **P < 0.005, ***P < 0.0001, NS not significant P > 0.05; PWV, pulse wave velocity; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
###end p 17
###begin title 18
Genetic and biochemical analyses
###end title 18
###begin p 19
###xml 143 147 142 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 236 238 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 429 431 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 519 524 518 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 532 534 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 537 541 536 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT </italic>
###xml 548 550 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 553 557 552 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT </italic>
###xml 564 566 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 572 576 571 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 585 587 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
Genomic DNA was extracted from an 80 mul aliquot of whole blood using standard phenol/chloroform methodologies with ethanol precipitation. The ACE I/D gene alleles (D and I) were identified by PCR amplification as previously described [15]. In order to reduce mistyping of ID heterozygotes as DD homozygotes, a re-amplification was carried out in all identified DD homozygotes using an internal primer specific for the I allele [15]. The other SNPs were identified following previously established PCR-RFLP conditions: AT1R A1166C [16], AGT M235T [17], AGT T174M [18] and ACE A11860G [19]. Amplification and digestion results were submitted to electrophoresis in silver stained T9C5 polyacrilamide gels.
###end p 19
###begin title 20
Statistical analysis
###end title 20
###begin p 21
###xml 716 718 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 734 736 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 807 809 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1129 1131 1127 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1260 1262 1256 1258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 2100 2102 2096 2098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 2103 2105 2099 2101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 2232 2235 2228 2231 <sub xmlns:xlink="http://www.w3.org/1999/xlink">00 </sub>
###xml 2258 2261 2254 2257 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10 </sub>
###xml 2482 2485 2478 2481 <sub xmlns:xlink="http://www.w3.org/1999/xlink">01 </sub>
###xml 2673 2676 2669 2672 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11 </sub>
###xml 2904 2906 2900 2902 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11</sub>
###xml 2913 2915 2909 2911 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10</sub>
###xml 2918 2920 2914 2916 <sub xmlns:xlink="http://www.w3.org/1999/xlink">01</sub>
###xml 2933 2935 2929 2931 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11</sub>
###xml 2939 2942 2935 2938 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10 </sub>
###xml 2946 2948 2942 2944 <sub xmlns:xlink="http://www.w3.org/1999/xlink">01</sub>
###xml 2951 2953 2947 2949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 2954 2956 2950 2952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 3013 3015 3009 3011 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11</sub>
###xml 3018 3020 3014 3016 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10</sub>
###xml 3023 3025 3019 3021 <sub xmlns:xlink="http://www.w3.org/1999/xlink">01</sub>
###xml 3029 3031 3025 3027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 3113 3116 3109 3112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11 </sub>
###xml 3117 3119 3113 3115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 2307 2313 <span type="species:ncbi:9606">people</span>
###xml 2519 2525 <span type="species:ncbi:9606">people</span>
###xml 2719 2725 <span type="species:ncbi:9606">people</span>
###xml 2788 2794 <span type="species:ncbi:9606">people</span>
In order to analyze the relative influence of genotypes and biochemical parameters among gender, the two groups (controls and patients) were each subdivided into male and female subgroups. Further grouping according to age (45 or less years old) was performed, aiming to analyse the association between genetics and early onset CAD. Individuals aged >/= 45 years were not included in this sub-analysis because no data about the age of CAD onset was obtained. Basic genetic parameters such as allele and genotype frequencies at each locus, proportion of individual heterozygous samples (direct count heterozygosity as well as the unbiased estimate) and population differentiation were calculated using Genepop v3.1d [20] and Arlequin [21]. Haplotype frequencies were calculated using the PHASE 2.0 software [22]. The overall genetic diversity, within each group diversity and the amount among groups were also calculated. Deviation from Hardy-Weinberg equilibrium per population and locus was calculated according to Weir and Cockerham FIS estimator using FSTAT v.2.9.3., with a Bonferroni correction for all significance levels [23]. Within all groups of subjects, distribution of allele and genotype frequencies and their differences were calculated using chi2 tests. Associated probabilities (P) were calculated applying Fisher's exact test adjusted for multiple comparisons of associated genotypes. To test the significance of association between genotypes at pairs of loci in each sample we used a log-likelihood ratio G-statistic as implemented in Genepop. The relative odds ratio (OR) and 95% confidence interval of relative CAD risk for any of the genetic polymorphisms and biochemical and behaviour markers, was assayed by logistic regressions using the SPSS package. To analyse possible positive or negative interactions between classical risk factors of CAD and genetic polymorphisms we used a 4 x 2 table approach and epiInfo 3.4.3 to calculate ORs, respective 95% confidence intervals and two-tailed p values, as well as synergy measures in additive (SI) and multiplicative models (SIM) [24-26]. It was assumed that unexposed individuals without the susceptibility genotype have a certain background risk for disease (OR00 is assumed to be 1); OR10 refers to the relative risk for disease among people without the susceptibility genotype for disease but exposed to the environmental risk factor relative to those with neither the susceptibility genotype nor exposure; OR01 refers to the relative risk among people with the susceptibility genotype who are not exposed to the risk factor relative to those with neither the susceptibility genotype nor exposure; OR11 is the ratio of disease risk among exposed people with susceptibility genotype to diseased risk among unexposed people without the susceptibility genotype. These ORs were then used in the calculation of synergy indexes: SI = (OR11-1)/(OR10+OR01-2), SIM = OR11/(OR10 x OR01) [25,26]; the relative excess risk due to interaction, RERI = OR11-OR10-OR01+1 [26]; and the attributable proportion of the disease due to interaction, AP = RERI/OR11 [26].
###end p 21
###begin title 22
Results
###end title 22
###begin title 23
Classical risk factors
###end title 23
###begin p 24
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 576 577 576 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 914 918 914 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 34 41 <span type="species:ncbi:9606">patient</span>
###xml 326 334 <span type="species:ncbi:9606">patients</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
As expected, both the control and patient group showed differences in the biochemical markers and other conventional risk factors analysed (Table 1). Systolic and diastolic blood pressure, dyslipidaemia, arterial hypertension, diabetes mellitus, triglycerides and a previous record of CAD in the family are much higher in CAD patients then in controls. In average, LDL was also higher in the CAD group and HDL values were lower in the patients group, as well as total cholesterol. We performed a multivariate logistic regression analysis using the variables included in table 1 and also the putative risk genotypes of RAS polymorphisms. We found HDL (OR = 0.91 95%CI: 0.89-0.93, p < 0.0001), glycaemia (OR = 1.01 95%CI: 1.01-1.02, p < 0.0001), CAD history (OR = 2.14 95%CI: 1.36-3.35, p = 0.001), smoking habit (OR = 1.81 95%CI: 1.11-2.93, p = 0.017), dyslipidaemia (OR = 13.18, 95%CI: 8.32-22.14, p < 0.0001) and ACE I/D DD polymorphism (OR = 1.72, 95%CI: 1.08-2.75, p = 0.022) to be independently related to CAD.
###end p 24
###begin title 25
Allele and genotype distribution
###end title 25
###begin p 26
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 337 341 337 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 349 350 347 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 352 354 350 352 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 403 407 401 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT </italic>
###xml 411 415 409 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 621 624 619 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 628 633 626 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 826 830 824 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 848 850 844 846 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 884 888 880 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 896 899 892 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 1055 1057 1049 1051 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1059 1062 1053 1056 <sub xmlns:xlink="http://www.w3.org/1999/xlink">10 </sub>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 225 233 <span type="species:ncbi:9606">patients</span>
###xml 561 569 <span type="species:ncbi:9606">patients</span>
Table 2 presents the distribution of genotypes for the 5 loci in controls and patients. Genotypes at both ACE loci show statistically different distributions for both the overall analysis and male subgroup. Only the group of patients is in Hardy-Weinberg equilibrium at each locus and overall as the control group is not at HWE at locus ACE I/D (chi2df1 = 7.55, P < 0.01). As expected, mutations at the AGT and ACE loci show strong significant linkage disequilibrium within each gene (P < 0.0001) for both groups, even after Bonferroni correction. The group of patients also shows significant genotypic disequilibrium at AGT235/AT1R (P < 0.03). An exact G-test for population differentiation gave an overall value of 0.00238 in which the loci contributing significantly to the differentiation between the two samples are both ACE polymorphisms (chi2 test, P < 0.0001 and P < 0.01 for ACE I/D and ACE11860, respectively). Thus taking in consideration all loci combined, both populations are significantly different concerning the genic differentiation (chi2 df10 = 24.082, P = 0.007).
###end p 26
###begin p 27
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Distribution of genotypes between patients and controls
###end p 27
###begin p 28
Values presentation: n(relative frequencies%); *P < 0.05, **P < 0.005, ***P < 0.0001, NS not significant P > 0.05.
###end p 28
###begin p 29
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 99 102 99 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 5 12 <span type="species:ncbi:9606">patient</span>
Male patient and control groups show significant differences in allele content at both ACE I/D and ACE11860 loci (P < 0.0001 and P < 0.05, respectively). This is also reflected on the distribution of genotypes across ACE I/D which is highly significant in a G-like test (P < 0.003).
###end p 29
###begin p 30
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 142 145 142 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 161 165 161 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 216 217 216 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 367 371 367 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
Analysing possible genotype associations of ACE polymorphisms and CAD development we obtained significant results when testing ACE I/D DD and ACE11860 GG, while ACE I/D ID genotype showed to decrease CAD risk (Table 3). The male population analysis resulted even more significant for these polymorphisms and no significant results where found in the female subgroup. ACE I/D DD genotype was shown to increase the risk of early onset CAD.
###end p 30
###begin p 31
Allele, genotype and haplotype association between ACE polymorphism and CAD and RAS combined set of alleles association with CAD
###end p 31
###begin p 32
###xml 120 128 <span type="species:ncbi:9606">patients</span>
Values presentation: OR(95% CI); *P < 0.05, **P < 0.005, ***P < 0.0001, NS not significant P > 0.05; CAD, number of CAD patients; C, number of control subjects.
###end p 32
###begin p 33
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
1Only combined set of alleles present in more than 10 individuals and yielding significant results are shown.
###end p 33
###begin title 34
Haplotype analysis
###end title 34
###begin p 35
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 35 38 35 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 177 180 175 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 188 192 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 274 277 272 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 285 289 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 345 346 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 393 397 391 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT </italic>
###xml 581 582 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 641 644 639 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 652 656 650 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 662 665 660 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 670 673 668 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 679 684 677 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 758 761 756 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 769 773 767 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 779 782 777 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 788 791 786 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 796 801 794 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
Within the ACE gene, the haplotype ACE11860 A/ACE I/D I was found to provide a decreased risk of developing CAD, except for the </= 45 subgroup analysis. An association between ACE11860 G/ACE I/D D and CAD was found in the whole population and male subgroup analysis, while ACE11860 G/ACE I/D I was associated with the disease in females (Table 3). No association was found when analysing the AGT gene haplotypes (results not shown). Considering all genes involved in the RAS system, only five out of nineteen obtained combinations yielded significant associations with CAD (Table 3), especially a male driven decreased risk provided by the ACE11860 A/ACE I/D I/AGT174T/AGT235 M/AT1R A combination and an increased probability of early onset CAD provided by ACE11860 G/ACE I/D D/AGT174 T/AGT235T/AT1R A.
###end p 35
###begin title 36
Interaction between RAS polymorphisms and classical risk factors
###end title 36
###begin p 37
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 160 163 160 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 218 222 218 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 270 273 270 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 349 352 349 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 741 745 741 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 753 756 753 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 766 771 766 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 925 929 925 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 1088 1092 1088 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 1133 1138 1133 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 1169 1173 1169 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 1401 1406 1401 1406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 1446 1450 1446 1450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 1686 1690 1684 1688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 1911 1912 1909 1910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 2026 2031 2024 2029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 2105 2109 2103 2107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 2357 2362 2355 2360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 2056 2064 <span type="species:ncbi:9606">patients</span>
###xml 2413 2421 <span type="species:ncbi:9606">patients</span>
The analysis of the possible positive/negative association between genotypes and classical risk factors is expressed in Tables 4 and 5, except for polymorphism ACE11860 GG, which rendered highly similar results to the ACE I/D analysis, so the results are not shown, and AGT174, with insufficient polymorphic data to perform this analysis. Regarding AGT235 TT or AT1R CC, we analysed only the whole population data, because the subdivision in sex or age classes rendered insufficient number of individuals to perform statistical analysis. Regarding the conventional risk of subjects unexposed to both classical risk factor and genetic risk (reference category) as being 1.0, the OR estimating the effect of joint exposure to hypertension and ACE I/D DD, AGT235 TT or AT1R CC was significantly higher than the ORs estimating the effect of each factor in the absence of the other. The synergy index in early onset CAD analysis (ACE I/D DD) was above 9, indicating a departure from an additive relation. In this group the proportion of CAD attributable to the interaction of hypertension and ACE I/D DD was as high as 85%. The genotypes AT1R CC in the overall analysis, or ACE I/D DD in all subgroups, interact with smoking habit to develop CAD, showing more than a multiplicative effect in females (SI = 0.86, SIM = 1.77, AP = 0.13). The risk provided by obesity was found to be positively reinforced by AT1R CC in the whole population analysis and ACE I/D DD in all subgroups, particularly in females (SI = 2.82, SIM = 1.79; AP = 0.46) and >/= 45 subgroup (SI = 4.13, SIM = 2.36, AP = 0.65). Performing the same analysis regarding diabetic individuals, significant results were found for ACE I/D DD carriers in the whole population analysis and a strong enhancement was found in females (SI = 5.04, SIM = 4.11, AP = 0.79), but not in males (SI and SIM < 1, AP < 0). None of the 2 polymorphisms presented in table 5 were found to interact with diabetes; nevertheless we must point that all 6 individuals carrying the combination AT1R CC and diabetes were CAD patients. The join presence of dyslipidaemia and ACE I/D DD interacts significantly in CAD onset, except in females (SI and SIM < 1, AP = -0.15). This combination was shown to be accountable for 89% of the disease in the = 45 years subgroup (SI = 9.19, SIM = 9.46, AP = 0.89). All 12 individuals with AT1R CC genotype and dyslipidaemia were found to be CAD patients, even though no significant results were obtained due to statistical constraint.
###end p 37
###begin p 38
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Synergistic effect of ACE I/D DD genotype and classical risk factors in CAD patients and controls
###end p 38
###begin p 39
SI, Rothman's synergy index for interaction; RERI, relative excess risk due to interaction; AP, proportion of disease attributable to interaction; *P < 0.05, **P < 0.005, ***P < 0.0001, NS not significant P > 0.05.
###end p 39
###begin p 40
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Synergistic effect of AGT235 MM and AT1R CC genotypes and classical risk factors in CAD patients and controls
###end p 40
###begin p 41
###xml 186 187 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
SI, Rothman's synergy index for interaction; RERI, relative excess risk due to interaction; AP, proportion of disease attributable to interaction; *P < 0.05, **P < 0.005, ***P < 0.0001; 1We performed no further subdivision when analysing these polymorphisms because several classes resulted statistically impossible to analyse due to the reduced number of individuals there included.
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 63 66 63 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT </italic>
###xml 551 555 551 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 602 606 602 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT </italic>
###xml 656 657 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
Previous studies have focused on the association of any of the ACE, AT1R and AGT gene polymorphisms with coronary events of several degrees, related or not with MI and essential hypertension. Up to know there is no consistent genetic pattern that may link a given haplotype to the risk of developing a CAD related syndrome or at least to make an individual more prone to be affected. All 5 gene polymorphisms surveyed here promote phenotypic variants on known mechanisms leading to changes in the biochemical status of an individual. For example, the ACE I/D variant is linked to ACE activity [10] and AGT M235T to different angiotensinogen plasma levels [3,14].
###end p 43
###begin p 44
###xml 165 169 165 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 312 316 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 513 517 513 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 638 639 638 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 344 347 <span type="species:ncbi:9606">men</span>
###xml 359 364 <span type="species:ncbi:9606">women</span>
###xml 433 440 <span type="species:ncbi:9606">patient</span>
By evaluating the distribution of RAS gene polymorphisms in a series of patients undergoing coronary angiography, the present study has shown that only mutations at ACE gene seem to be linked to CAD and even these are apparently male-linked because no such association was visible in females. The association of ACE I/D DD genotype with CAD in men but not in women, has been reported previously in several studies [27,28]. While our patient subpopulation was in Hardy-Weinberg equilibrium for I/D polymorphism of ACE gene, the control subpopulation was not, due to an excess of heterozygotes ID. Similar results were previously reported [5,29] and may be interpreted as a case of heterosis, or even confirm the higher risk homozygotes DD have to develop CAD.
###end p 44
###begin p 45
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 144 147 144 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 446 450 446 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 760 764 760 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
The deletion polymorphism of the ACE gene has been shown to be associated with both CAD and MI [5,30,31]. The mechanism by which the ACE I/D or ACE11860 genotypes may predispose an individual to the development of MI remains unclear. ACE is responsible for the conversion of angiotensin I to the peptide precursor angiotensin II, which has been implicated in the pathogenesis of atherosclerosis [32,33]. In contrast, other studies concluded that ACE polymorphisms did not influence the development of MI or other manifestations of CAD [34,35]. There are several possible reasons for these discrepancies: besides the different genetic backgrounds of the study populations, some of the studies cited have only minor statistical power or the associations between ACE gene polymorphisms and CAD or MI have been restricted to relatively small subgroups. Even more, in some studies, the presence or absence of CAD was not determined by angiography and might even have used false-negative control populations. These findings also stress the necessity of considering ethnic factors in the assessment of genetic risk identifiers.
###end p 45
###begin p 46
###xml 44 47 44 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT </italic>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
The total lack of association between the 2 AGTs and AT1R polymorphisms and CAD is in agreement with other studies [14,36] that found no relation between these polymorphisms with CAD albeit a strong association between AGT variants and angiotensinogen levels. Nevertheless, our study revealed a significant influence of the A allele and AA genotype of AT1R upon an increase in carotid-femoral PWV values, which may be regarded as a risk factor for CAD (results not shown).
###end p 46
###begin p 47
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 34 37 34 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 389 393 389 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 403 406 403 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 561 564 561 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 572 576 572 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 582 585 582 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 591 594 591 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 600 605 600 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
The presence of the ACE I/D I and ACE11860 A alleles in ACE haplotypes corresponds to the lowest risk of developing CAD in the whole population, male and female subgroups, expressed by ORs lower than 1. When analysing the influence of RAS haplotypes in the development of CAD, it is clear that the major influence comes from both ACE polymorphisms. Yet again, the simultaneous presence of ACE I/D I and ACE11860 A alleles, corresponds to a significant trend towards a decrease in CAD, both in male subgroup and overall analysis. The combined set of RAS alleles ACE11860 G/ACE I/D D/AGT174 T/AGT235 T/AT1R A was the only one found to significantly increase CAD risk in the whole population analysis. No significant association was found in females, showing once again the interest of separating this type of data between sexes.
###end p 47
###begin p 48
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 613 616 613 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 624 628 624 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 634 637 634 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 643 646 643 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 652 657 652 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 170 176 <span type="species:ncbi:9606">people</span>
###xml 1163 1171 <span type="species:ncbi:9606">patients</span>
###xml 1273 1281 <span type="species:ncbi:9606">patients</span>
Premature CAD is known to have a particularly strong genetic component. Previous data have suggested that genetic factors are more likely to affect young rather than old people [37]. We conducted a population subdivision, analysing separately individuals who developed CAD before the age of 45. We found no significant allele or genotype association between any of the 5 polymorphisms and early onset CAD. The only significant results were found when associating the RAS combined set of alleles with the disease, where individuals under 45 have a 2.47 relative risk of CAD occurrence when in the join presence of ACE11860 G/ACE I/D D/AGT174 T/AGT235 T/AT1R A. Here we must point the impossibility to further subdivide this group according to sex, due to small sample size, as a limitation to perform a more thorough analysis. One should be aware that in almost all case-control studies, particularly those involving haplotype analysis, problems related to multiple comparisons (even when statistically corrected), the potential influence of genetic and environmental factors not considered, limited sample size for subgroup analysis and the possible inclusion of patients with silent CAD in the control group should be taken into account. The fact that the control and CAD patients groups are not sex and age matched may also be regarded as a constraint in the study design.
###end p 48
###begin p 49
###xml 953 957 953 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 1076 1079 1076 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
###xml 1134 1135 1134 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 1305 1309 1305 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 1679 1681 1679 1681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1770 1773 1770 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 1783 1788 1783 1788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 1967 1971 1967 1971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 1988 1990 1988 1990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 2025 2027 2025 2027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 2442 2446 2442 2446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 2514 2516 2514 2516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 3009 3013 3009 3013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 3075 3079 3075 3079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT </italic>
###xml 3082 3087 3082 3087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 3088 3090 3088 3090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 3151 3154 3151 3154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 3182 3187 3182 3187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 3245 3250 3245 3250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1R </italic>
###xml 3299 3302 3299 3302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGT</italic>
###xml 3459 3461 3459 3461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 3488 3492 3488 3492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 3658 3660 3658 3660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 3706 3708 3706 3708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 3262 3270 <span type="species:ncbi:9606">patients</span>
The complex aetiology around cardiovascular disorders and the multiple environmental conditionings are most of the times not evaluated together. In most cases, CAD has a multifactorial genetic basis, involving a number of genes and environmental factors interacting to determine whether or not the disease will develop. Therefore, the inherited genes generally predispose to a greater or lesser extent of CAD, but it is the environmental factors (e.g. cigarette smoking, obesity, hypertension, sedentarism) interacting with the individual's genotype that determine whether or not CAD will develop. We performed further analysis in order to determine whether the simultaneous presence of genetic polymorphisms and well established risk factors - hypertension, smoking habit, obesity, diabetes and dyslipidaemia - would enhance the effect in CAD onset of these last. Some interesting results were obtained, particularly in the subgroups analysis. As both ACE polymorphisms have shown to be in strong linkage disequilibrium, we chose not to show the results of this analysis for ACE11860 GG. They are very alike those presented in table 4 as the exact same associations were found with similar, yet slightly lower values. We found a proportion of CAD attributable to the interaction between hypertension and ACE I/D DD genotype around 30% for the whole population and male subgroup analysis. In the early onset CAD analysis, this proportion goes up to 85%. The vascular risk factors that might be related to serum ACE activity are not yet fully understood. Nevertheless, a previous study has shown a correlation between male sex and history of hypertension with serum ACE activity [38], which may partially support our findings. This effect was also found when considering AGT235 TT or AT1R CC as the risk genotypes (SI = 1.44, SIM = 1.36, AP = 0.25; SI = 1.79, SIM = 1.47, AP = 0.38, respectively). Smoking may increase ACE levels by means of a nicotine enhancement of ACE gene expression [39]. A large population based study [40] found a positive association between the D allele of the I/D polymorphism and carotid artery thickness among smokers: individuals carrying only one of the risk factors did not show significant differences in artery thickness when compared to non-smokers with II genotype, while carriers of both risk factors had significantly higher artery thickness. In our study we found a synergistic effect due to smoking and ACE I/D DD join presence, which is in accordance with a previous study [41]. Moreover, these authors found a positive association between total high cholesterol, high LDL or overweight/obesity and the DD genotype. In the present report we also found this association, concerning dyslipidaemia and obesity. This synergy effect is particularly striking when considering the early onset CAD subgroup analysis (obesity: SI = 4.13, SIM = 2.36, AP = 0.65; dyslipidaemia: SI = 9.19, SIM = 9.46, AP = 0.89). Obesity and hypercholesterolemia have been shown to play a role in ACE gene expression, but also in other RAS intervenients, such as AGT or AT1R [42]. Nevertheless, we found no association between obesity and AGT235 TT or dyslipidaemia and AT1R CC, even though all 12 dyslipidaemic individuals carrying AT1R CC were CAD patients. A similar study, analysing AGT235 T allele synergistic effect with several risk factors, found a positive association with hypercholesterolemia but neither with hypertension nor smoking [43]. The association between ACE I/D polymorphism and Type 2 diabetes has been rather controversial. Some studies have affirmed a clear association between DD genotype and the disease in Caucasians [44] while others have excluded this hypothesis [45]. We found a female driven synergistic effect of DD genotype together with diabetes (SI = 5.04, SIM = 4.11, AP = 0.79).
###end p 49
###begin title 50
Conclusion
###end title 50
###begin p 51
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE </italic>
###xml 231 234 231 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACE</italic>
The most relevant findings of this research are based on the influence of RAS gene polymorphisms evaluated together with the presence of the main classical risk factors for CAD, showing how at least two polymorphisms - ACE I/D and ACE11860 A/G - interact synergistically with them in CAD onset. Taking into account that CAD is a multifactorial disorder driven by numerous environmental, behavioural and genetic components interacting together, our results seem to corroborate the hypothesis that RAS gene polymorphisms may indeed enhance the influence of traditional risk factors in CAD development. The sample used in this study is also a novelty because it is based on the population of Madeira Island that until the beginning of the 20th century was a relatively isolated island. To our knowledge this analysis on such a population had not yet been performed. Madeiran inhabitants with a history of a small founder population, long lasting isolation and population bottleneck represent an exceptional resource in the identification of genes involved in the pathogenesis of multifactorial diseases.
###end p 51
###begin title 52
Competing interests
###end title 52
###begin p 53
The authors declare that they have no competing interests.
###end p 53
###begin title 54
Authors' contributions
###end title 54
###begin p 55
AIF performed this work as part of her PhD thesis, under guidance of AB and AC. AB, IM and RPR conceived the idea for the study. Lab and clinical data were performed under AB, IM and AC guidance. All authors performed data analysis, interpretation and discussion of results and also read and approved the final manuscript.
###end p 55
###begin title 56
Pre-publication history
###end title 56
###begin p 57
The pre-publication history for this paper can be accessed here:
###end p 57
###begin p 58

###end p 58
###begin title 59
Acknowledgements
###end title 59
###begin p 60
This study was supported by contract POCTI/38697/MGI/2001 (co-financed by POCI 2010 and FSE) from Foundation for Science and Technology, Ministry of Science, Technology and Higher Education (Portugal). AIF is recipient of a PhD research fellowship under contract SFRH/BD/8592/2002. The authors are indebted to Dr. Jose Jesus for valuable criticisms over the data analysis.
###end p 60
###begin article-title 61
Polymorphisms in the RAS and cardiac function
###end article-title 61
###begin article-title 62
Genetics of hypertension
###end article-title 62
###begin article-title 63
Association analysis of a polymorphism of the angiotensinogen gene with essential hypertension in Japanese
###end article-title 63
###begin article-title 64
Enhanced predictability of myocardial infarction in Japanese by combined genotype analysis
###end article-title 64
###begin article-title 65
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potential risk factor for myocardial infarction
###end article-title 65
###begin article-title 66
Five polymorphisms in genes candidates for cardiovascular disease in afro-Brazilian individuals
###end article-title 66
###begin article-title 67
Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls: International Studies of Infarct Survival (ISIS) Collaborators
###end article-title 67
###begin article-title 68
Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention
###end article-title 68
###begin article-title 69
Searching for a better assessment of the individual coronary risk profile
###end article-title 69
###begin article-title 70
Synergistic effects of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on risk of myocardial infarction
###end article-title 70
###begin article-title 71
Signficance of angiotensin I-converting enzyme and angiotensin II type I receptor gene polymorphism as risk factors for coronary heart disease
###end article-title 71
###begin article-title 72
Nine polymorphisms of angiotensinogen gene in the susceptibility to essential hypertension
###end article-title 72
###begin article-title 73
The involvement of the renin-angiotension system gene polymorphisms in coronary heart disease
###end article-title 73
###begin article-title 74
Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study
###end article-title 74
###begin article-title 75
Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism
###end article-title 75
###begin article-title 76
DdeI polymorphism in the AGTR1 gene
###end article-title 76
###begin article-title 77
###xml 75 80 <span type="species:ncbi:9606">human</span>
Rapid detection of the hypertension-associated Met235--> Thr allele of the human angiotensinogen gene
###end article-title 77
###begin article-title 78
Angiotensin Gene Polymorphism M235T/T174M. No Excess Transmission to Hypertensive Chinese
###end article-title 78
###begin article-title 79
Linkage and Association Analysis of Angiotensin I-Converting Enzyme (ACE)-Gene Polymorphisms with ACE Concentration and Blood Pressure
###end article-title 79
###begin article-title 80
GENEPOP (V.1.2) A population genetics software for exact tests and ecumenicism
###end article-title 80
###begin article-title 81
A new statistical method for haplotype reconstruction from population data
###end article-title 81
###begin article-title 82
FSTAT, a program to estimate and test gene diversities and fixation indices (version 2.9.3)
###end article-title 82
###begin article-title 83
Synergy and antagonism in cause-effect relationship
###end article-title 83
###begin article-title 84
Confidence intervals for measures of interaction
###end article-title 84
###begin article-title 85
Evolving methods in genetic epidemiology III. Gene-Environment interaction in epidemiologic research
###end article-title 85
###begin article-title 86
###xml 90 93 <span type="species:ncbi:9606">men</span>
###xml 98 103 <span type="species:ncbi:9606">women</span>
Angiotensin II type-I receptor and ACE polymorphisms and risk of myocardial infarction in men and women
###end article-title 86
###begin article-title 87
Sex difference in the effect of ACE-DD genotype on the risk of premature myocardial infarction
###end article-title 87
###begin article-title 88
Angiotensin-converting enzyme and p22phox polymorphisms and the risk of coronary heart disease in a low-risk Spanish population
###end article-title 88
###begin article-title 89
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary artery disease in non-insulin-dependent diabetes mellitus
###end article-title 89
###begin article-title 90
A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study
###end article-title 90
###begin article-title 91
###xml 45 50 <span type="species:ncbi:9606">human</span>
Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro
###end article-title 91
###begin article-title 92
###xml 109 112 <span type="species:ncbi:10116">rat</span>
Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells
###end article-title 92
###begin article-title 93
A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction
###end article-title 93
###begin article-title 94
A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemic heart disease
###end article-title 94
###begin article-title 95
Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease
###end article-title 95
###begin article-title 96
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Role of family history in patients with myocardial infarction: an Italian Case-Control study. GISSIEFRIM Investigators
###end article-title 96
###begin article-title 97
Angiotensin converting enzyme polymorphism and carotid wall thickening in a community population
###end article-title 97
###begin article-title 98
###xml 47 52 <span type="species:ncbi:9606">human</span>
Nicotine induced changes in gene expression by human coronary artery endothelial cells
###end article-title 98
###begin article-title 99
A study of gene-environment interaction on the gene for angiotensin converting enzyme: a combined functional and population based approach
###end article-title 99
###begin article-title 100
Modification of the coronary artery disease risk associated with the presence of traditional risk factors by insertion/deletion polymorphism of the ACE gene
###end article-title 100
###begin article-title 101
###xml 27 32 <span type="species:ncbi:9606">human</span>
Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension
###end article-title 101
###begin article-title 102
The M235T polymorphism of the AGT gene modifies the risk of coronary artery disease associated with the presence of hypercholesterolemia
###end article-title 102
###begin article-title 103
The D allele of the ACE I/D common gene variant is associated with Type 2 diabetes mellitus in Caucasian subjects
###end article-title 103
###begin article-title 104
The angiotensin-I converting enzyme I/D polymorphism is not associated with type 2 diabetes in individuals undergoing coronary angiography. (The Ludwigshafen Risk and Cardiovascular Health Study)
###end article-title 104

